Merck Now Confirms: “We’re Buying All SmartCells Shares” — Back Bay Angel Funds Win Big


Here was my overnight piece on the rumor — now it’s a fact:

From Merck’s press release — of an hour ago:

. . . .Under the terms of the agreement, Merck will acquire all outstanding stock of SmartCells, Inc. In return SmartCells shareholders will receive an upfront cash payment and be eligible to receive clinical development and regulatory milestones for products resulting from the transaction for potential aggregate payments in excess of $500 million. Sales-based payments for products resulting from the transaction will also be payable. SmartCells’ board of directors has unanimously approved the transaction. . . .

My reaction? In view of these uncertain life sciences development market conditions, that’s a pretty heady valuation — for a company with no revenue and no proven product in any clinical trial. even so, it may turn out to be a very favorable price, if this nano-tech approach pans out in patient trials. We’ll keep you posted.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s